Abstract

DEVELOPMENT AND EVALUATION OF PEGYLATED SOLID LIPID NANOPARTICLES OF TORSEMIDE

Likhitha C. N.*, Ashok Kumar P. and Manjunath K.

ABSTRACT

The goal of this project is to develop PEGylated Solid lipid nanoparticles with a sustained release. Suitable lipids (Tristearin, GMS), stabilizer (Soy lecithin), surfactants (Tween 80 and span 20) and Polyethylene glycol (PEG) as PEGylating agent were selected. Hot homogenization followed by ultra-sonication technique was used to develop PEGylated Solid lipid nanoparticles of Torsemide. Particle size, PDI, Zeta potential, Drug content, percentage drug entrapment efficiency, in vitro drug release studies and release kinetics were evaluated on the produced nanoparticles. According to FT-IR drug-excipient compatibility investigations, there was no interaction between drug and selected lipids. The particle size ranged from 44.90 to 157.7 nm. PDI of all formations were upright within the range of 0.285 to 0.572, Zeta potential ranged from -15.2 mV to -38.8 mV, Percentage drug entrapment efficiency of all formulations were perceived were in the range of 86.24% to 95.75 %. The cumulative percentage release of Torsemide ranges from 66.39 % to 86.1 % from different formulations. Amongst all formulations, the formulation F8 displayed highest drug release of 86.1% and contemplated as good formulation. The kinetic data of formulation F8 exhibited first order release and the release mechanism was Anomalous (non-Fickian) diffusion. The developed PEGylated SLNs exhibits sustained drug release upto 12 hours.

Keywords: Torsemide, PEGylation, FT-IR, In vitro drug release.